Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis

Single-agent poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved as the first targeted therapy available for patients with BRCA-mutated HER2-negative metastatic breast cancer. This meta-analysis aimed to better evaluate activity, efficacy and safety of single-agent PARPi in thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Poggio, Francesca, Bruzzone, Marco, Ceppi, Marcello, Conte, Benedetta, Martel, Samuel, Maurer, Christian, Tagliamento, Marco, Viglietti, Giulia, Del Mastro, Lucia, de Azambuja, Evandro, Lambertini, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6012556/
https://www.ncbi.nlm.nih.gov/pubmed/29942664
http://dx.doi.org/10.1136/esmoopen-2018-000361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6012556/
https://www.ncbi.nlm.nih.gov/pubmed/29942664
http://dx.doi.org/10.1136/esmoopen-2018-000361

Ejemplares similares